Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy
Advanced Healthcare Materials · 2026-11-11
DOI: 10.1002/adhm.71963 ↗Abstract
ABSTRACT Hyperlipidemia is a systemic metabolic disorder closely associated with chronic inflammation. Effective management requires integrated strategies that simultaneously lower lipid level and attenuate inflammation. Nucleic acid therapeutics, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) siRNA, represent a breakthrough in lipid‐lowering therapy. However, they either lack direct anti‐inflammatory effects (GalNAc‐siRNA) or are prone to triggering unintended inflammatory responses themselves such as lipid nanoparticles (LNPs). Milk‐derived extracellular vesicles (MDEs) emerge as naturally anti‐inflammatory nanocarriers that suppress key pro‐inflammatory cytokines by 30.0%–96.5% in vitro. However, MDEs predominantly undergo endocytic trafficking with substantial endosomal/lysosomal sequestration, which can limit productive cytosolic siRNA delivery. To address this, we developed engineered MDEs by incorporating 30.0% ( w/w ) probiotic‐derived glycolipids into their membranes to facilitate early endosomal escape. When loaded with PCSK9 siRNA, the engineered MDEs achieved a remarkable silencing efficiency of 90.2 ± 0.2%, significantly outperforming both unmodified MDEs and conventional LNPs. In hyperlipidemic mice, systemic administration of engineered MDEs improved serum lipid profiles, reduced lipid accumulation and systemic inflammation, and showed a favorable safety profile under the conditions examined. Collectively, this work provides a promising nucleic acid delivery platform based on engineered MDEs for enhanced hyperlipidemia therapy through simultaneous lipid‐lowering and anti‐inflammatory effects.
EUVIMED